{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"0"}]}],"title":"At least 1 ABI-007 dose delay/Not given"},{"categories":[{"measurements":[{"groupId":"OG000","value":"295"},{"groupId":"OG001","value":"230"}]}],"title":"At least ≥ 1 Gem dose delay/Not given"}],"denoms":[{"counts":[{"groupId":"OG000","value":"421"},{"groupId":"OG001","value":"402"}],"units":"Participants"}],"description":"The number of dose delays or doses not given experienced by participants during the treatment period. Dose delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities. Treatment delays of no longer than 21 days allowed participants to recover from acute toxicity, otherwise participants were discontinued from further treatment except in the event of peripheral neuropathy.","groups":[{"description":"Albumin-bound paclitaxel (ABI-007)/Gemcitabine: ABI-007 125 mg/m\\^2 administered intravenously (IV) in combination with Gemcitabine 1000 mg/m\\^2 IV weekly for 3 weeks on Days 1, 8, and 15 followed by one week of rest","id":"OG000","title":"Albumin-bound Paclitaxel (ABI-007)/Gemcitabine"},{"description":"Gemcitabine 1000 mg/m\\^2 administered IV weekly for 7 weeks through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks on Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward)","id":"OG001","title":"Gemcitabine"}],"paramType":"NUMBER","populationDescription":"Treated Population","reportingStatus":"POSTED","timeFrame":"Up to 666 days","title":"Number of Participants With Dose Delays/Doses Not Given","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"number of dose delays"}